Do albendazole-loaded lipid nanocapsules enhance the bioavailability of albendazole in the brain of healthy mice?
Albendazole
Lipid nanocapsules
Neurocysticercosis
Pharmacokinetics
Taenia solium
Journal
Acta tropica
ISSN: 1873-6254
Titre abrégé: Acta Trop
Pays: Netherlands
ID NLM: 0370374
Informations de publication
Date de publication:
Jan 2020
Jan 2020
Historique:
received:
29
05
2019
revised:
04
10
2019
accepted:
05
10
2019
pubmed:
11
10
2019
medline:
14
2
2020
entrez:
11
10
2019
Statut:
ppublish
Résumé
Neurocysticercosis is a neglected tropical disease that affects the central nervous system and is the most common cause of human epilepsy acquired in developing countries. Therapeutic failures attributed to medical management of neurocysticercosis with albendazole (ABZ) have been primarily linked to the poor drug absorption rate resulting in low drug level in plasma and brain tissue. The aim of the current work was to characterize and compare the brain pharmacokinetic behavior of ABZ formulated as a suspension or lipid nanocapsules (ABZ-LNCs) in healthy mice. The relative availability in brain tissue of the active metabolite ABZ sulphoxide increased 183% when ABZ was administered as LNCs, in relation to ABZ suspension. The parent drug was also detected for a short period of time. The bioavailability of ABZ in ABZ-LNCs treated mice increased more than 2 fold compared with ABZ suspension group. The enhanced drug brain exposure observed after administration of ABZ-LNCs to healthy mice has potential usefulness for the treatment of human neurocysticercosis.
Identifiants
pubmed: 31600525
pii: S0001-706X(19)30713-2
doi: 10.1016/j.actatropica.2019.105215
pii:
doi:
Substances chimiques
Anthelmintics
0
Lipids
0
Nanocapsules
0
Albendazole
F4216019LN
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
105215Informations de copyright
Copyright © 2019. Published by Elsevier B.V.